Drawing for CORAVA

USPTO serial 50089561

CORAVA

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
—
Law office
—

What this means

Status 630 means your trademark application is in the USPTO queue and has not yet been assigned to an examining attorney. This is normal shortly after filing. Examination typically begins within three to four months, though timing varies. Wait for assignment and the first examiner action. Monitor TSDR monthly for status changes to 638 (assigned) or an office action.

Status 630: Status 630 means your trademark application is in the USPTO queue and has not yet been assigned to an examining attorney. This is normal shortly after filing. Examination typically begins within three to four months, though timing varies.

Need help with CORAVA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Gregory B. Coy

Gregory B. Coy Taft Stettinius & Hollister LLPOne Indiana Square, Suite 3500Indianapolis, IN 46204United States

Goods and services

ClassDescriptionStatusFirst use
001Lipids for use in the manufacture of pharmaceuticals and lipid-based chemical preparations for use in the manufacture of pharmaceuticalsACTIVE—
005Pharmaceutical preparations for the treatment of cancer; drug delivery agents consisting of compounds that facilitate delivery of pharmaceuticals; pharmaceutical preparations utilizing lipid nanoparticle delivery technology for the treatment of cancer; Chemical preparations for pharmaceutical or medical purposes, namely, for use in the manufacture of pharmaceuticalsACTIVE—
042Pharmaceutical research and development; Scientific research in the field of of lipid nanoparticle drug delivery systems; research and development of pharmaceutical preparations for the treatment of cancerACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 3, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Sep 3, 2026NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance